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Background: Abacavir is a widely-used nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency 
virus (HIV) infection. Mandatory postmarketing surveillance was conducted in Korea to monitor the safety and evaluate the ef-
fectiveness of Ziagen® (abacavir sulfate 300 mg; ViiV Healthcare, Middlesex, UK).
Materials and Methods: An open-label, multi-center, non-interventional postmarketing surveillance study was conducted from 
June 2010 to June 2016 to monitor the safety and effectiveness of Ziagen across 12 hospitals in Korea. Subjects older than 18 
years taking Ziagen according to prescribing information were enrolled. The primary outcome was defined as the occurrence of 
any adverse events after Ziagen administration. Secondary outcomes included the occurrence of adverse drug reactions, occur-
rence of serious adverse events, and effectiveness of Ziagen administration.
Results: A total of 669 patients were enrolled in this study, with a total observation period of 1047.8 person-years. Of these, 
90.7% of patients were male. The mean age of patients was 45.8±11.9 years. One-hundred ninety-six (29.3%) patients reported 
315 adverse events, and four patients reported seven serious adverse events, without any fatal events. There was one potential 
case of an abacavir hypersensitivity reaction. Among the 97 adverse drug reactions that were reported from 75 patients, the 
most frequent adverse drug reactions included diarrhea (12 events), dyspepsia (10 events), and rash (9 events). No ischemic 
heart disease was observed. In the effectiveness analysis, 91% of patients achieved HIV-1 RNA under 50 copies/mL after 24 
months of observation with abacavir administration.
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Introduction
 
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) 
used for the treatment of human immunodeficiency virus 
(HIV) infection. In combination with other antiretroviral 
agents, abacavir has proven antiretroviral efficacy, which is at-
tributable to its ability to reduce HIV-1 replication and improve 
immunologic parameters [1-4]. Abacavir is one of the first-line 
recommendations among NRTIs in many international treat-
ment guidelines [5-7]. It can cause hypersensitivity reactions, 
especially in patients who are positive for the HLA-B*5701 al-
lele, and the association of abacavir and ischemic heart disease 
remains inconclusive based on available data [8-12]. Zia-
gen®(abacavir sulfate 300 mg; ViiV Healthcare, Middlesex, UK) 
was first approved in Korea in 2001 as an orphan drug and lat-
er became available on the market in 2010. We carried out a 
postmarketing surveillance study to evaluate the safety and ef-
fectiveness of Ziagen in a real-world setting.
Materials and Methods 
1. Study design and population
An open-label, multi-center, non-interventional postmarket-
ing surveillance study was conducted from June 2010 to June 
2016 to monitor the safety and effectiveness of Ziagen across 
12 hospitals in Korea. Patients with confirmed HIV infection 
taking Ziagen according to prescribing information were in-
cluded. Subjects who started Ziagen before the study period 
were also included, and the observation started on the day 
consent was obtained. Patients with contraindications for aba-
cavir described in the prescribing information, such as moder-
ate to severe hepatic impairment (Child-Pugh class B or C), 
end-stage renal diseases (estimated glomerular filtration rate 
≤15 mL/min/1.73 m2 or those receiving renal replacement 
treatments), or confirmed HLA-B*5701 carriers, were exclud-
ed. The primary outcome was defined as the occurrence of any 
adverse events (AEs) following Ziagen administration. Sec-
ondary outcomes included the occurrence of unexpected ad-
verse drug reactions (ADRs), occurrence of serious adverse 
events (SAEs), and the effectiveness of Ziagen administration. 
Effectiveness was assessed via measurement of changes in 
plasma HIV-1 RNA viral load and CD4+ T-cell counts for each 
participant during the study period. Regarding the non-inter-
ventional study design, a subjective assessment of clinical im-
provement was also included for the subjects whose observa-
tion period on the study was over 24 weeks. A total of 780 
subjects were planned to be enrolled, with an estimated 20% 
drop out rate, in order to provide 600 evaluable subjects for the 
primary analysis. This study was approved by the Institutional 
Review Board of each participating hospitals.
2. Definitions
Based on WHO-ART 092, an AE was defined as any untow-
ard medical occurrence in a subject temporarily associated 
with the use of Ziagen, whether or not considered related to 
the medicinal product. An SAE was defined as any untoward 
medical occurrence at any dose that (1) results in death, (2) is 
life-threatening, (3) requires inpatient hospitalization or pro-
longation of existing hospitalization, (4) results in persistent or 
significant disability/incapacity, or (5) results in a congenital 
anomaly/birth defect. An ADR was defined as all noxious and 
unintended responses related to Ziagen. Physicians classified 
the relatedness of the event to the drug into 6 categories (cer-
tain, probable/likely, possible, unlikely, conditional/unclassi-
fied, and unassessable/unclassifiable) by WHO-UMC causality 
categories [13]. If the causality between Ziagen and AEs is con-
sidered certain, probable/likely, possible, conditional/unclas-
sified, or unassessable/unclassifiable, the AEs were classified 
as ADRs. ADRs that are not listed in the Korean prescribing in-
formation were classified as unexpected ADRs.
3. Demographic and clinical data 
Physician visits were scheduled in accordance with each 
Conclusion: Our data showed the safety and effectiveness of Ziagen in a real-world setting. During the study period, Ziagen 
was well-tolerated, with one incident of a clinically suspected abacavir hypersensitivity reaction. The postmarketing surveil-
lance of Ziagen did not highlight any new safety information. These data may be helpful in understanding abacavir and the HIV 
treatment practices in Korea.
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physician’s routine practice. At the initial visit, demographic 
information (including subject’s sex, age, height, body weight, 
and pregnancy status); medical history (including allergy his-
tory, renal impairment, hepatic impairment, other concomi-
tant diseases, treatment duration of Ziagen, time since HIV di-
agnosis, and HIV treatment history); concomitant medications; 
laboratory values (including viral load); and CD4+ T-cell counts 
were recorded. Physicians were guided to record any treat-
ment-emergent AEs during the follow-up visits. Results of all 
HIV-1 RNA viral loads and CD4+ T-cell counts performed with-
in the study period were collected. At the final study visit, the 
effectiveness of Ziagen was subjectively evaluated as improved, 
no change, worsened, or not assessed based on the investiga-
tor’s medical judgment. 
4. Statistical analysis
Continuous variables were expressed as the mean ± one stan-
dard deviation, and discrete variables were expressed as the 
frequency and rate. Once all AEs were classified by preferred 
terms and system-organ classes, the frequency and percentage 
of each AE were calculated. Because of the non-interventional 
design of the study, not all subjects had their HIV-1 RNA viral 
loads and CD4+ T-cell counts evaluated every 3 months. Test 
results without an exact date and invalid test results were ex-
cluded from the analysis. The available values were collected 
for each 3-month time frame, and the ratio of participants with 
HIV-1 RNA <50 copies/mL and mean CD4+ T-cell counts were 
calculated. Statistical calculation was carried out using SAS ver-
sion 9.0 (SAS Institute Inc, Cary, NC, USA).
Results
1. Characteristics of study participants
Data were collected from 671 patients; however, due to 2 cas-
es of protocol deviation, 669 patients were included in safety 
analysis. The total observation period was 1047.8 person-years. 
The majority (90.7%) of included patients were male. The 
mean age of patients was 45.8 ± 11.9 years. Patients older than 
65 years and those diagnosed with HIV infection within the 
past year represented 6.9% and 16.4% of the population, re-
spectively. The majority of patients (63.8%) took abacavir with 
another NRTI plus a boosted protease inhibitor (PI). Patients 
with concomitant diseases represented 70.3% of the popula-
tion; eight patients had renal impairment (chronic kidney dis-
ease stage 2 to 3 [14]); 43 patients had hepatic impairment 
(Child-Pugh class A score; Table 1).
2. Safety and tolerability
One-hundred ninety-six patients reported 315 adverse events. 
The incidence of diarrhea (23/669, 3.4%) was the highest, fol-
lowed by that of dyspepsia (19/669, 2.8%), dizziness (18/669, 
2.7%), pharyngitis (15/669, 2.2%), and rash (14/669, 2.1%).
Four patients reported SAEs. A 72-year-old man presented 
with nausea, vomiting, fever, and lethargy after 54 days of Zia-
gen administration. His symptoms resolved within 24 hours of 
stopping Ziagen use. HLA-B*5701 allele status was not avail-
able. The investigator reported that this case may possibly be 
Table 1. Baseline characteristics of the subjects included in safety analysis
Total, n (%) 669 (100)
Male gender, n (%) 607 (90.7)
Age, mean (SD), y 45.8 (11.9)
18-64, n (%), y 623 (93.1)
65-80, n (%), y 46 (6.9)
BMI, mean (SD), kg/m2 22.3 (2.9)
Time since HIV diagnosis, mean (SD), y 4.4 (4.0)
Less than 1 year, n (%) 110 (16.4)
2-5 years, n (%) 267 (39.9)
6-10 years, n (%) 216 (32.3)
Over 10 years, n (%) 61 (9.1)
Duration of Ziagen administration observation, n (%)a
Less than 3 months 120 (17.9)
4-12 months 424 (63.4)
Over 12 months 125 (18.7)
ART regimen at study registration, n (%)
Ziagen + 1 NRTI + NNRTI 145 (21.7)
Ziagen + 1 NRTI + PI 427 (63.8)
Ziagen + 1 NRTI + INI 49 (7.3)
Others 50 (7.5)
History of any allergy, n (%) 12 (1.8)
Any concomitant diseases, n (%) 470 (70.3)
Renal impairment 8 (1.2)
Hepatic impairment 43 (6.4)
Cardiovascular diseases 101 (21.5)
Concomitant drug use, n (%)
Antihypertensive drugs 92 (13.8)
Glucose-lowering drugs including insulin 39 (5.8)
Lipid-lowering drugs 99 (14.8)
aSubjects who started Ziagen before the study period were also included; the ob-
servation began on the day of consent.
SD, standard deviation; BMI, body mass index; ART, antiretroviral therapy; NRTI, 
nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse tran-
scriptase inhibitor; PI, protease inhibitor; INI, integrase inhibitor
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an abacavir hypersensitivity reaction. Other presentations of 
cellulitis, abscess formation, and general weakness were deter-
mined to not be associated with use of the study drug (Table 2).
Seventy-five patients reported 97 ADRs. Diarrhea was the 
most common ADR (12/669, 1.8%), followed by that of dys-
pepsia (10/669, 1.5%), rash (9/669, 1.3%), nausea (7/669, 1.0%), 
and dizziness (5/669, 0.7%; Table 3).
In addition to the one possible case of abacavir hypersensi-
tivity reaction, no further cases of abacavir hypersensitivity re-
action were reported in this study. No cases of ischemic heart 
disease were reported. 
3. Effectiveness 
The proportion of patients who achieved HIV-1 RNA <50 
copies/mL increased over time during Ziagen treatment (Fig. 
1). A total of 669 patients had initial HIV-1 RNA viral loads. Ini-
tially, 44.6% of patients had viral loads below 50 copies/mL; 
but, after 24 months of abacavir administration, 90.8% of the 
76 patients who had a 24-month HIV-1 RNA blood test 
achieved HIV-1 RNA under 50 copies/mL. In addition, the 
mean CD4+ T-cell count increased from 334.7 cells/mm3 at 
baseline to 577.6 cells/mm3 after 24 months of abacavir treat-
ment (Fig. 2). Excluding 158 subjects whose observation dura-
tion was less than 24 weeks, 511 of the 669 patients were eligi-
ble for the subjective effectiveness analysis. Three-hundred 
sixty-nine patients (72.2%) were rated as improved, 30 (5.9%) 
were rated as unchanged; 5 (1.0%) were rated as worsened; and 
107 (21%) were non-assessed. 
Discussion
This was a postmarketing surveillance study of 669 patients 
in Korea designed to observe the safety and effectiveness of 
Ziagen.
A 3-drug regimen with a 2-NRTI backbone plus one core 
agent (non-nucleoside reverse transcriptase inhibitor [NNRTI], 
PI, integrase inhibitor [INI]) has become the standard treat-
ment of HIV infection. Abacavir is one of the most commonly 
used NRTI backbones, which is recommended in major inter-
national treatment guidelines in combination with dolutegra-
vir and lamivudine [6, 7, 15]. Abacavir is also available as a 
fixed-dose combination as abacavir/lamivudine and dolute-
gravir/abacavir/lamivudine. 
A total of 669 patients were included in the 6-year postmar-
keting surveillance study. Due to the introduction of the aba-
cavir/lamivudine fixed-dose combination in 2012 in Korea, re-
cruitment of subjects has been slow since 2014. Most patients 
were recruited between 2011 and 2013. Male patients account-
ed for 90.7% of the total study population, reflecting a 
male-dominant sex ratio in Korea [16, 17]. In terms of the an-
tiretroviral therapy regimen (Table 1), 63.8% of patients used 
abacavir with another NRTI and a PI. In comparison with oth-
er NNRTI dominance in other Asian countries during the 
study period, our data reflect the popular use of PI-based regi-
mens in Korea [18, 19]. Since INIs were only introduced in 
2010, a small portion of patients was taking an INI with abaca-
vir in Korea. Although we set HLA-B*5701 carrier status as an 
exclusion criterion, HLA-B*5701 allele status was unknown in 
all subjects.
Although generally well tolerated, there have been reports of 
AEs related to abacavir [1, 20]. In this study, there were four 
SAEs; however, none of the SAEs were certain or probable/like-
ly linked to the use of Ziagen by investigator assessment. There 
was one patient (Case 1 in Table 2) presenting with nausea, 
vomiting, fever, and lethargy on the 54th day of abacavir ad-
ministration whose condition improved within 24 hours of 
drug cessation. This case is a clinically suspected abacavir hy-
persensitivity reaction based on the presenting symptoms and 
time of resolution after abacavir cessation. Abacavir hypersen-
sitivity may occur in 5% to 8% of patients and requires careful 
attention, as it can be life threatening without appropriate 
management [21, 22]. Abacavir hypersensitivity is strongly as-
sociated with the HLA-B*5701 allele; thus, genotypic screening 
Table 2. Clinical characteristics of cases with serious adverse events
Age Gender Adverse event Treatment duration Outcome Drug cessation
Association with 
Ziagen
1 72 M Nausea, vomiting, fever, 
lethargy
54 days Resolved Yes Possible
2 80 M Foot cellulitis 209 days Resolved No Unlikely
3 44 M Liver abscess 282 days Resolved No Unlikely
4 40 M General weakness 7 days Resolved No Unassessable
M, male.
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is recommended before the use of abacavir-containing prod-
ucts [8, 23-25]. Research reporting the incidence of HLA-B*5701 
varies considerably by ethnicity, and its prevalence can be as 
low as 0.3% to 0.5% in Korea [26-28]. A report showed no 
HLA-B*5701-positive HIV-infected patients in a study of 534 
Korean subjects (95% confidence interval [CI], 0.00-0.69) [28]. 
This report raised a question about the cost-effectiveness of 
HLA-B*5701 testing versus careful patient monitoring for aba-
cavir hypersensitivity reactions after prescribing abacavir in re-
gions with a very low incidence of the HLA-B*5701 allele. In 
our study, the incidence of abacavir hypersensitivity was 0.09 
(95% CI, 0.0048-0.4700) per 100 person-years of follow-up. 
Although the risk of ischemic heart disease and the use of 
abacavir were not associated in several recent meta-analyses 
[10, 11], the overall evidence is inconclusive [9, 12]. In the pres-
ent study, no patients using abacavir had evidence of ischemic 
heart disease. Similarly, no abacavir-related cardiovascular 
events were observed in the postmarketing surveillance study 
Table 3. Frequency and expectedness of adverse drug reactions
Number Incidence, % Listeda
Gastrointestinal
  Diarrhea 12 1.8 Yes
  Dyspepsia 10 1.5 Yes
  Nausea 7 1.0 Yes
  Abdominal pain 2 0.3 Yes
  Vomit 4 0.6 Yes
  Oral ulcer 1 0.1 Yes
Respiratory tract
  Pharyngitis 1 0.1 Yes
  Cough 1 0.1 Yes
  Increased sputum 1 0.1 No
Skin and appendages
  Rash 9 1.3 Yes
  Pruritus 4 0.6 No
  Urticaria 2 0.3 Yes
  Increased sweating 1 0.1 No
  Skin nodules 1 0.1 No
  Dermatitis 1 0.1 No
Nervous system
 Dizziness 5 0.7 Yes
 Numbness 1 0.1 Yes
Systemic disorders
  Fever 2 0.3 Yes
  Worsened general  
condition
1 0.1 No
  Fatigue 1 0.1 Yes
  Generalized ache 2 0.3 Yes
  Flush 1 0.1 No
  Chills 1 0.1 Yes
  Weakness 1 0.1 Yes
  Edema 1 0.1 Yes
Psychiatric disorder
  Sleep disorder 2 0.3 Yes
  Loss of appetite 4 0.6 Yes
  Lethargy 1 0.1 Yes
  Bad dreams 1 0.1 Yes
Metabolic disorder
  Hypertriglyceridemia 4 0.6 Yes
  Hyperlipidemia 1 0.1 Yes
  Hypercholesterolemia 1 0.1 Yes
  Dyslipidemia, Unspecified 1 0.1 Yes
Hepatobiliary system
  Hyperbilirubinemia 2 0.3 Yes
  Elevated ALT 3 0.4 Yes
  Elevated AST 3 0.4 Yes
  Jaundice 1 0.1 Yes
Total 97 events (75 patients)  
aAEs listed in Korean prescribing information.
ALT, alanine transaminase; AST, aspartate transaminase; AE, adverse event.
Figure 1. Proportion achieving HIV-1 RNA <50 copies/mL. 
aMissing test date or unknown test results.
Figure 2. Changes in CD4+ T-cell counts. 
aMissing test date or unknown test results.
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of abacavir and abacavir/lamivudine in Japan [20, 29]. 
The incidences of ADRs were considerably low in our study. 
The most frequent ADRs reported were gastrointestinal (GI) 
disturbance, including diarrhea (12 cases, 1.8%), dyspepsia (10 
cases, 1.5%), and nausea (7 cases, 1.0%). It is difficult to identify 
abacavir-specific AEs, since abacavir was used in combination 
with other medications including antiretroviral drugs and oth-
er concomitant drugs. It is interesting to note the low incidence 
of GI AEs, despite the high proportion of subjects (63.8%) tak-
ing boosted PI–based regimens in Korea, which is lower than 
the 10% reported incidence of GI disturbance in the postmar-
keting surveillance report in Japan [20]. The lower incidence of 
GI-related AEs in Korea may require further investigation. 
In the effectiveness analysis, we assessed the proportion of 
patients achieving plasma HIV-1 RNA <50 copies/mL. There 
were 44.6% of 669 patients with suppressed viral load at the 
start of study. After 24 months of an abacavir-containing treat-
ment regimen, 90.8% out of 76 patients who had HIV-1 RNA 
results at 24 months achieved plasma HIV-1 RNA under 50 
copies/mL. The mean CD4+ T-cell count increased from 334.7 
cells/mm3 at baseline to 577.6 cell/mm3 after 24 months of an 
abacavir-containing treatment regimen. Without a well-con-
trolled comparator arm, it is hard to evaluate the effectiveness 
of abacavir as a single agent; however, we could observe a nu-
merically positive virologic and immunologic effect of abaca-
vir-containing antiretroviral therapy from this study.
This study has several limitations. Firstly, it is a postmarketing 
surveillance study with limited variables. We could not collect 
actual laboratory results such as serum creatinine and liver en-
zymes. Secondly, due to the observational study design, inter-
ventions for study participants, including prescheduled blood 
test intervals, were not allowed; the data were inconsistent with 
regard to the duration of abacavir use or specific intervals of in-
dividual viral load testing. Lastly, the study does not include a 
comparator arm; thus, it is hard to directly attribute the positive 
effectiveness data solely to the antiviral activity of abacavir. 
These data may provide supportive information to healthcare 
practitioners, as our study results reflect positive real-world 
data of HIV treatment using an abacavir-containing regimen. 
In conclusion, we report in a postmarketing surveillance 
study the real-world data from 669 patients using abacavir. Ab-
acavir was generally well tolerated. The incidence of abacavir 
hypersensitivity was rare. Cardiovascular AEs were not report-
ed with the use of abacavir in this study. More patients 
achieved plasma HIV-1 RNA <50 copies/mL with abacavir ad-
ministration than baseline, and the CD4+ T-cell count was in-
creased from baseline. These results may be helpful for under-
standing abacavir use and HIV treatment patterns in Korea. 
We are collecting further safety and effectiveness information 
for abacavir from spontaneous reports and postmarketing sur-
veillance of other drugs containing abacavir.
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